<SEC-DOCUMENT>0001129928-13-000034.txt : 20130524
<SEC-HEADER>0001129928-13-000034.hdr.sgml : 20130524
<ACCEPTANCE-DATETIME>20130523182046
ACCESSION NUMBER:		0001129928-13-000034
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130523
FILED AS OF DATE:		20130524
DATE AS OF CHANGE:		20130523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13869677

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of May 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">News Release Dated&#160;&#160;May 22, 2013:<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>Oncolytics Biotech&#174; Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;May 23, 2013</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Kirk Look</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="onclogo.jpg" alt="Logo"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- May 22, 2013</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the Cancer Therapy &amp; Research Center at the University of Texas Health Science Center (CTRC).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eligible patients include those with metastatic malignant melanoma who have failed one or more prior therapies or those not considered a candidate for standard first line therapy. The primary objective of the Phase 2 trial is to assess the antitumour effect of the treatment regimen in the study population in terms of objective response rates. The secondary objectives are to assess progression-free survival and overall survival for the treatment regimen; the disease control rate (complete response (CR) plus partial response (PR) plus stable disease (SD)) and duration, and to assess the safety and tolerability of the treatment regimen in the study population.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The study is a two stage design. Up to 18 evaluable patients with metastatic melanoma were to be treated in the first stage. If three or more patients demonstrated a PR or better, the study could then proceed to the second stage, with up to 43 patients being treated in the entire study. This endpoint was met after 14 evaluable patients were enrolled.&#160; Three of 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Past research has indicated that human melanoma cell lines were highly permissive to reovirus type 3 Dearing in <font style="FONT-STYLE: italic; DISPLAY: inline">in vitro</font> experiments, and that intravenous administration of the virus as a monotherapy resulted in significant tumour growth retardation. A subsequent Phase 2 monotherapy intravenous administration clinical study demonstrated viral replication in biopsy samples of patients. A Phase 1 all comers intravenous administration clinical study in combination with docetaxel demonstrated partial response and stable disease outcomes in a small (four) melanoma patient subpopulation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;These preliminary results are very encouraging and support progressing to subsequent studies,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;Past clinical research has shown that REOLYSIN delivered intravenously replicates in melanoma tumours, and this is the second clinical study to demonstrate responses in patients with REOLYSIN in combination with other therapeutics.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The emergence of genotyping and increasingly targeted therapies is changing how cancer is treated. As a result of recent and potential additional near-term changes to the standard of care for the treatment of melanoma which include agents targeting B-Raf and PD-1, Oncolytics is now conducting research to evaluate REOLYSIN in combination with other emerging treatments for a number of patient sub-populations. The Company intends to continue with a follow on clinical study in melanoma once this research is concluded.&#160;&#160;On that basis, the second stage of this clinical trial will not proceed at this time.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 metastatic melanoma cancer trial, future trials in this indication, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research, development and manufacturing of pharmaceuticals, changes in technology, general changes to the economic environment and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@tmxequicom.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dian Griesel, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Susan Forman</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">396 West Broadway, 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">sforman@dgicomm.com</font></font></div>
</td>
<td valign="top" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'4!]`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/[^
M****`"BBB@`HJ*:40H7;`502Q/``'4DD@`>K,0H')('-?E9^U-_P6`_9%_9I
MGU'PU;^(;_XP?$6R>6"X\(?##[%JMII=W$64V_B+Q=/=P^&]+994:&ZMK&\U
MC6+*0,L^DJ58#SLPS7+\JH_6,PQ5'"TK-Q=2:4IV5VH0=G)VZ*Y<(3J2481<
MFS]6**_C:^+_`/P7W_:O\97=U:_"?P?\._A!H[LPLY'LKCQ_XK2,L`C3ZIK7
MV/0G<AHRRP>$5VDL%RWRGY[3]M#_`(*X?%0G5/#_`(Z_:8URVE(E23X>_#S4
M[/3E5_N&,>#/!MI;-#M&$'S(>I.<Y^'J^)^1W:P.#S;,DI6<\-A+0MKJI5)Q
M36UE>[O=*QU?4:JUE*G'IK+KIHUT>OWZ']U-%?PK2_M5_P#!7_P&#J^J>+OV
MM=)@BVN;GQ=\/_$MYI@P3@/#XF\(W6G@9Y82*H<9!##BO4_AE_P77_;?^'E[
M':?$-?`/Q8LK=RE[9>*?"0\,^(,1G$D<6I^%)-!M[>4`!6FN]#O421FS;L`'
M?*GXIY+[14\9E^;X'F:7/6P]%Q2?VI*-?F276R;79A]1JNW+.G)]N>VG?7\C
M^U:BOQ*_9D_X+E?LL_&2XL/#GQ5L]8_9^\87[Q0)+XHGCUSX>W-VQ6,Q0>-=
M/MK5]-4RMS-XET'0+"%656OW;K^T6D:OIFNZ?::MHVH6>K:7J%O#>:?J6G7,
M%Y87UG<('@NK.\MI);>ZMIDP\,\,CQRQE71V1E)^ZRO.\JSFE[;+,=0QD%;F
M]E+WH7Z3@TI1:ZII?D<U2E4HRY:D;/IU3]&MT:=%%%>H9A1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%>>_$[XH>!/@[X'\1?$?XD^)-/\`"7@SPK92ZCK>N:I.(;>VMXL!8XDR
MTUU=W4A2VL;*VCENKV[EBM;2&6>5$/::EJ5CH]C=:GJ=S!8Z=8V\]W?7UU+'
M;VEE:6L,EQ<W=U/*R106T$,3R332.J1JI+$"OXD?^"D/[<?C_P#;_P#CSI_P
M;^#"ZUJOP@T3Q:/#WPO\(:/'.;GXE>*I;AM.C\:ZE9H%,\U_,[Q^&[.\C2'1
MM#V75Q%!J-_K#O\`*<5\34>',#&I&#Q&/Q4E0P&$AK.M6G91DXK50B]^_0Z<
M+0]O5Y6[1BG*;UTBOU?0ZW]NO_@K%\;_`-L'Q)<_!W]GF#Q7X&^$>LZB/#^E
MZ%X=2];XB_%66[G%I;IK+Z8\E_;V&INWEVGA/2G5)(I@-8N-1<1PV?OO[&__
M``0:\:>.;32_'/[6?B/4/AUHMTL-[;?##PO):2^-[JVDVS8\2ZQ-'>:9X8FG
M5OWNG6MKJ.J1L9([LZ==)L7]7O\`@FE_P3!\#?L=^%[#X@>/;'2/&'[1/B'3
MDDU?Q#+%'?:?X`M;RW&_PSX,2=&2">*-C:ZUXCB5+S56:>VM7M]*=H+C]<50
M*`-JC&1P!W_"OE,GX'KYO6_MSC*K6QF,KN-6AEKJ2CA<+#3DA4I+2:4-/9NR
MU?-=G15Q<:7[K"PA&*2O42NY-))ZO>[UOW5SY*^"'["_[)_[/5O8Q_"WX'>!
M-'O[)$5/$NH:1#XB\6S2(H7S9O$_B'^TM;W':/DCNXXD/$4<:`*/K1(HHU"1
MQ1H@X"(BJH'H%```'8`8%245^F83!83`TU2PF&H8:G%*,84*:IP222244M%I
MHMDK+H>>Y2EK)MMZOU&E%(P54CI@J,8/48QWKP'XO_LL?L\_'FSELOBU\&_A
M[XW$T#0&_P!7\-Z?_;MNK#AK'Q#:PV^MV$BG!26SOX70C(/2OH"C'M^E:5\/
M0Q,'3Q%"C7A+>%:G&I%^JDFO1].@XSE%J46TULS^9;]KC_@@-HES::IXN_9#
M\6W.E:I&DUT/A1X_U%[W2K[;F7[)X=\92J;W3YFP4MK?Q)]NMV9@EQK5NA$B
M_EW^S-^V_P#M;?\`!-#XGW?PL\<Z-XEE\(:1JH@\9?`OQZ]Y:Q6D<KEKC5?!
MES<B0Z%>7<3FYL-3TCS_``_KV^*YN(KV*9;@?W6$`]0#]1FOA7]N;]@OX1_M
MN_#R3P_XMLK;P_\`$'1;2ZD\`_$S3K.#^WO#E^RL\=E>$*CZQX9O9F*ZIHES
M,$:-Y+G3I;#4U@OH?SK.^!O83>;\*57E.:4'[;V%"T<+BG"UZ<J?PKGBFDMK
MOS.REC-/9XB*JTGIKNGI9W>NCUWULKW/8/V9OVG_`(2?M7?##2_BI\(]?75=
M'O2MIJ^EW1AM]?\`"FN1VZ7%YH'B731+(^GZE:APR$%[:_M7@U'3IKNPN(;J
M3Z+K^#+X,?%7]HC_`()+?M<ZKH'BC3[RWATV_M='^*'@9+AF\.?$GP'-=M+8
M:_H5S(L,$TC6F_6/!NO1QQ2V5X]SI6I?N6UW2I/[B/A-\4O!?QJ^'?A+XH_#
MS5X]=\'>--%L]<T34H^/,MKI6WV]Q'DO;7]C.DMEJ-G+B:SO8)K:91+$X'L<
M(\5+/Z-;"XNDL)G.`?)CL(TXMO;V].,O>Y)2:YDWI)Z:-&>*P_L91E!N5&:3
MC-[IV3<';KNUY'HM%%%?9G*%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%(3CK_*@#\&/^"Z?[7=Y\(?@?I'
M[/?@[56LO&OQT6]_X226UF,=WIGPQTR5(=5BRFYXAXMU%UT$$J!/IEMKT7S`
M-CPK_@A'^Q!8Z=X=N_VQOB'HT<^L>(&U'P]\%;34($=M,\/VLLVF^(?&T,4F
MX1W>LWL5WH6D7/\`K8M,L]2ECDEMM4BFD_+#]OWQ7KW[9O\`P4S\5>!?#MS)
M=I=?$_P[^SWX%5=\D%I9:-K%MX5N[J(*S$PW&OW6O:U(RI\L-TQ8#:[K_;K\
M-?`'ASX6?#_P3\./"-DFG^&O`GA;0_">A6BC!ATS0M.M].M=Y_CGDCMUDN)2
M2\T[R2NS.Q)_)<EHKBOC+-,[K_O,NR.JL#EU-MNE.O'>LD[^]3:YEHKR>NAZ
M%22P^&ITX:5*J<JCZ\C2LN:]]6GY.VG6_:(H55`4#``Z?_6'7O\`K3Z**_6E
M>RN[NRN^_F>>%%%%`!1110`4F`>WM^=+10!^-'_!9+]B.P_:0^`-W\4_!VCQ
M'XP?`_2M1\0:9-9Q*+[Q1X$M$^V>)_",RQIYMY+:VL<NOZ`C>:\%_9W5C9K#
M_;EU)7YS?\$"_P!KF[T?Q1XI_9#\8ZH[:3XDM]2\>?"A;J5B+'7M+@^T^,O#
M-H)-I6'5=+C;Q+;P(JHD^E:Q*JL]ZS5_55<017,4D,Z+)%*CQ21N-R2)(NQT
M=3PRNI*E2"#G.,@5_!O^TAX;U/\`X)]?\%*=8U/PE!-8:3\.OBWH?Q1\&VD(
M\I9_`_B*]A\2IHB'$9ELVTO4=1\+7"@,C1031EF1I(Q^3<8TGPWQ#E7%N#BZ
M<:]>G@<U4=(UJ;<$G):1NZ7,HMOXZ;;MHST,,_K%&IAIWM']Y3=]K<M_.]].
MW+]S_O*C)QACDX'\N3]#Z9J2LG0]5L->TG2]<TJX2[TS6=-L=6TZZC.4N=/U
M*VBO+*Y0]"DUO*DBD=01UK6K]6IN+A!P?-"48RC*]^:,DI)W>ZL_\KZ'GZIM
M.VCTM?;_`#"BHO,4$Y<8!(^A';.,9&".O7KS4F<XQD@\YQQ5<R>B:;[)J]NX
M"T45&SA6Y;@=1@]<=,XP">,9(SD`4[VWT_S[>H$E%(#D9'\B/T/-+0`444QV
MV\YVCN<<8_SVH;MOIY@/HJ#S!G&\9`R1ANGUVU(C9SSN]"!QCZXQGVSQ^-*_
MR?9[]/ROJ&O5->H^BBBF`44UF`!)..<9QGGTQ49DP<;P,X`R.IQVX^N?2E=7
MMU[=?6W8":BF*P)QN!..F._?W_/UI]-.^VOH`444TL`<$]NF/KST]L?TI-VZ
M7U\M%W=^WW@.HJ/S$R!G)/H">^.PZ_\`Z^@)J2G<`HHIK.J8W'&?8G^0/K1<
M!U%-WKZ_S_S[GT&3T!IP.>:+@%%%1LZ\@-\PZ@`M^&`"<GL,9.,=:3E&-KM*
M[LK]6!)13=P*ALY![CO_`/K/%)YB?WA[YR#^''Z^G(SFB_W=]+/\;_@`^BF>
M8G]X4>8G]X4<R[K[P'T4S>G]X4X,&Z>N.F/_`*].]]@%HIK,J_>./_U@?J3Q
M_P#6-"L&&1C\""/S%*^J7>_X6Z?U8!U%%%,`HI"<?Y]B?Z5$9.1\X&>1D'I]
M=N,\],Y_`$T!KV)J*8K@G'?U]2.OX]\=<<T^DG?^D_R;`***C9PN<GIV_P`K
M_(_UH;MT;]$W\WY>8$E%1F11_%P!D],`>IS_`/JI0ZDXSR/7'?I^?:A23V_K
M;_/\QV?9_</HHHIB"BBB@`KGO$VJKH?A_6]<DSLT;1]1U5^,C9864UW(2.^1
M#M`P22<=-U=#7!?$N&2X^'/CVVA5GFG\%>*8(D7J\LVAWZ1J`,Y8E_E'4G@<
MX!Y\5.<*%6=--SC2K2C;O&E.2_%(J/Q1O_-'\T?Q0_\`!)'0S\5_^"E?P[\1
M:V!?26&H?$OXF7TDPWF34H-`UV>SN]Q+$2Q:WJEE=*^[<&C#!LJ&']S2Y"J#
MU``/4]O4\_GSZU_$5_P0RN(K+_@H!X:MKA@DUW\.OB790*>/,N8])AN6C&<<
MB&UGDP!G$9.,`U_;L#GFOSOPMA!9%C*B=YU,WQKJ/JVIKXGNVKM*^R]3MS'^
M.O*$4ON6WD%%%%?IAP!1110`4444`%%%%`#6ZK['/Z@?UK^0S_@X8\%0:1^T
M/\%/'4$*QR>,_A7J6C7<JJ`;FZ\&^)IY`SX7YC%:>)[-`79ONKL`"#;_`%YG
MJ/\`/\2U_*A_P<9:A;OXY_9;TM?*-Y;>$_B=?3`#]]';7NL>$+>V)YXBGEL+
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MIJOCS6[/]F[]K_7_`++\19=1N-,\"_$_6H+72%\1ZA]IFB_X0GQO%%;65MIW
MBF&YS;:+J0@M8=758]+U%8]:C@N-;_'S_@K7.;7_`(*4_&VZ`.;;7/A_<`@D
M%3!X)\)R@C!#9!3@(5<DX5@>1^L?_!5[_@EQ>_$'3[O]K?\`9LT%F\:/IT/B
M+XL?#[0K?R;CQ5OM(;NX\=>%;&V4/+XGA"F76]*MPEQK4:C4+/?J<,\.H_B>
M#QO$T,ZXES?+<7BL=')<UG"ME5:M5J4*V!JRJ1E&E3<W&,Z2A>GRQ7):\=K/
MU>6A*CAJ-2*A[6FIJK&,5+G6B7-NW+9IZ/SV/Z6%8.`RYQSVZ^_T]#WZ]*_D
M_P#^"P'[;G[5WP(_;(U#P!\(OC?XP\">#8?AYX$U:+P_H:Z/'9Q7^IP:C]ON
M]UQI<]S+)<O&K2O+-(1M2./;'&J+[1_P2:_X*S7'B6Y\-?LM?M0>(2OB0M:Z
M%\*OBAK4HB.OS*KV]EX'\9W]R5)\0.RPVWA[7;E@^N7!72M0?^U7L9-3^"O^
M"]UNT7[<=C<D+Y5]\&O`4\#+_&(]4\2VS;F[L#;N!@D;0`<&OHN+^*89GP=3
MS/)\9B,)7CCL+2Q4:-:>'Q.$JN,G.A6=*:E&[<6K2:DG%O6Z6&&P[AB>2I!.
M,HRY'))Q=FFGU6WKJUZG]?OP/UO5?$OP7^$?B37;R34=;\0_#+P%KFL:A*L:
M2W^J:MX4TF^U"\E2%(XDDNKN>:>18HXXP[G9&BX4>H,VU68\!5))]`!DFO&_
MV<O^3>O@3_V1OX8_^H5HE>NWL[6MG=W*Q/.UO;3SK!'_`*R9HHGD$4>>-\A7
M8N>-Q%?JV%DY83#2DW*3P]&4F]6VZ<6VV]VWJV]V<$OCDMO>:\EJ?ES^WW_P
M5.^$?[$T:^$+2P?XG?&O4-/2_L?`&F7L5E8>'[6Y'^AZEXXUD1W,FC070(EL
M=*MK.ZUC4$\N3R+*PF_M%/SA^&/BO_@M'_P4%TZ#X@>%_''A+]EOX-:T3+H=
M]!I<?A<:K8;V*7>@QRZ7XN^(>L0F)D6+4KC4=)T'4P'GL+H`;4_"WX<W]]^U
M-^W'X#N?BW=R:K/\9?VB?#$?C-[IY'273_$OC73X-1TR-F?S(K&'3WFTBW@1
MXUM;"..UA6**&)%_T+],TW3])L;;3-,M8+*PL;>"SM+.VC6&VM;6UB2"VM[>
M!`L<$$,$4<4,,2I%'&BHBA0*_+\BQ>9<=XW,<7B,PQF79+@:].CA\MR^M+"U
ML1)T_:1J8G%TTJO+.#3E2B^52T3:LSMJPAA:=.T5*M4BIN4DIPBM'RJ,E9O7
M5VZ*Q^"5S_P3+_X*2Q6HU&Q_X*A>.;GQ!CS#I]W'XZM-%\WN@OH_&-^WED\C
M=X?*`?\`+$'BO<?V1?@C_P`%9OAW\6(;3]H?]I+X;>-O@GIBBXO0=-M_%_B3
MQ.?]6FGZ1>3>&/!NN:!(R_O9]3U75-0@M&14@TG4C-)Y/[&45]AA^%,!A*]+
M$8?%9O3G2DI\G]K8Z=*HU:T:M*=5PJ1W5I)[OO9<\Z\JD7&4:=GU5.*DO22L
MT`S@9Z]_K7RS^UM^UO\`"O\`8X^%&H?%3XHZA<-"L[:;X:\+Z6D4WB+QGX@>
M"6>VT/1+::2&(2%(7N+W4+B2.RTRQ26\N691%'-]35_'_P#\'"?C#7[_`/:6
M^$W@:XN9_P#A&?#?PE&OZ79%C]E.K>*/$^MVVKWOE;BK3M:Z#I=JTK*3Y4*J
MA568.N,L[K\/Y!BLRPU+VM>$J=&E%NRC.O+DC4??V;][E>DMG8K"45B*\:;=
MD]7Z*USV7P%^VQ_P52_X*3^*_$6E?LIV7@_X"?#+0[N*VUCQ.(+":RT.*Z`D
MM[+6O'OB'0];U'5_$,T(^T"V\$>%[&2*W>)[BTLXG6XD^H+?_@F?_P`%(]5M
M_P"T/$7_``5#\;:=KD@$DEEHEMXXN]+64G<8TNAXR\.JD0?(S%HB!E/$*CY*
M^GO^"+?A[P_HG_!/GX-7VC0P+>^)+[XAZ]XAN(]OG7FM?\+!\2:0SW3*,RS6
M^FZ3I=FCR;G6WMH(=V(5`_5M?NC\?YUXV1\.?VMEF#S//,TS/,<9CJ$,1/V>
M88G"86C[3WHPHX?"3HQARQ]UWOYIEUJKI59PI0A&$7RZPA.3:MJY2BV[[O9+
MHC^9[XL>"O\`@M'^P_H6I?$_0_V@M+_:6^&WAB&35/$=E=:?'XGU.ST>U7S+
MN]UKP[XCT6/Q0-,MH@9+JY\)>*KV\M[=9[N]2VLX9)H/K+_@GG_P6'\#_M::
M]IWPC^*VAZ?\+?C3>HZ:$NGW4MSX(^($]O$9+BUT"XO6DO\`1-?PDTT7AN_G
MU,7=O$TNG:W=3![.+]IKJ""YM[B"YBBG@FCEBFAE0212Q.FR2*2-@RR(Z,RN
MA4A@2I!!(/\`G;?&JT/P+_;6^)]G\/'ET@?"S]I+Q6G@LV.Z"72X_"WQ&OVT
M&&T8L73[%';P01%F8LJ;I-Y9MWB<28C'<"XO*L5E^/QV*RK&XB>'Q65X_$U,
M4ERJ,E+#5ZO-6I)1=E%3UVE>[:WH0AC(5(SA&-:$>>,X)035G[LE%6=][V;\
MNI_HI(<J#G.?;'MCMR#U]^*^(O\`@H[\2/''PB_8M^//Q$^&_B*]\)^-O#7A
MC3;G0?$6G);/?:9<7/B;1-/FGMA=P7,`E:TN[B%7>%VC\SS(RDJHZ_96A7<E
M_HNDWTR%)KW3K*ZF0C!26XMHY9$([%'8H1V*U^?W_!63_E'Q^TK_`-BCHW_J
M9>'*_1LZJSCD>95J<I4YK+L14A.+<9PE["4HN,DTXR3M9IW3LT<-)7K0BU=<
MZ371ZGYE_P#!$#]KC]I']HSXK_&W0OC?\7/$_P`1])\/>`?#NK:+9:__`&:8
M].U&?Q%):375NUG86DH>6V8Q2*TC1LH4E-RJ1_22#R1Z8_6OY*?^#=;_`)+=
M^T-_V3#PQ_ZE3U_6J/O-^'\J^;\.,5B<7PM@J^*Q%;$UI5<2I5:]6=6HU&<.
M5.=1RD[7=M;)/3J;XV,8UYJ,5%<E-V225VHW=D.KR+XY_#SQ)\4OAIXD\&^#
M_B3XI^$?BK4K0MX>^(/@^2%=7\/:Q;$3V-P]O<H\.H:;+,BP:KIS^4UY8R3P
MQ7-I.T=S%Z[2$`]>U?;UJ4:]*I1GS*%2+A)Q;C))JWNR33C+^646I1=I1U2.
M1;_\"Y_&MK?[<W_!2+_@GO\`M/6WA7]I?QOXE^*F@:7=YU'PSXEN+:Y\+?$;
MP9/<;%U[P+X@_LR":QOWA0W&GW49DFT[4HGTO7=/E47=@O\`5C^SM^T3\+_V
MG?AEH'Q7^$_B./7?#6MP*D\#B*+6/#^L0I&=0\/>(]/1Y9-+UK3Y)`ES;2/(
MDB-%=VD]S87%I=7'FG[9W[&'PH_;/^%5W\/OB!8BRUJR^T7O@CQW8V\4GB#P
M7KLD.Q;VSE?:USIMT$C@UG19I1::I:*(V$=U%:7-O_)!\/\`XE?M4?\`!&W]
MIOQ'X1U_2/[5TF]MY%UOPI/?W4'@+XI^'-]S'H/B[P]?^7*L5W:7#++%J,=N
M-3TV8:GH>JVZL9H5_*ZN-S3@',?]OQ&-S3A;&SM#%UN?%8C+:\FG"@Y2G*I)
M2=[2O9Q]YI/W7Z"A#%P7LXPA72LXQ2C&2C975DW>RNV];[Z-6_JT_;L_;S^%
MO[$7POD\4^))X?$'Q#U^.ZM?AO\`#:VNE@U3Q/J<<;(U]J!V22Z5X4TJ9HY-
M8UMXF5?W=E9+<ZA<P6S_`(8_L+>/_P#@I_\`\%!_BOJWC"Y_:&\<_##X"Z=X
MCDO/&FO^&M/T+2=)A61A<KX$^&MG=Z/=+/J:VS16[7ES)>IH%K)'J6K7.I7M
MQ#9W_P`O_LL?LK?M"?\`!7#]H/Q-\=/C=KNM6/PLM=;B_P"$T\:@26\,T-I(
MMS9?##X7VUP'@M6M+*>&*6XA26R\.6,RZA?->:W>0VU]_8[\,/A=X$^#G@?P
MW\.OAOX;T_PGX/\`"FF0Z5HNB:9"(;>VMX@2\DAYDN;NZF9[F\O;EY;N\NI9
M;FXFDFED=NC+99SQGF-/-J]7&95PWA)WP&$HU*V&K9E)3LL17E!PE[*\?@O*
M,D[;$551H0G27[RK)1O-Q5H[<RB[\R];*^ODCL+6V:TTZUL_-NIVM;:"V^T7
M<PFO)O)C6'S[FXX\ZYDV^9/-@&24O(!DA3^)?Q6_8^_X*S^(OB9X]\0?#O\`
M;P\.>%_`6M^+M?U3P;X:N$U6SF\/>&K_`%*XNM'T6:"T\#ZG;K)I=C)!8LT5
M]<+,T)F\P[\+^XE-;@9]/\:^[S'*,/FD*-.O5QM*-&2<?J>-Q&$E)62Y9SHS
MC*:TNN9[NYR4YN#O%0;:Y??BI)7ZV>ET?R<_MJV7_!6']A_X::#\3_'W[<3>
M+=&U_P`7VO@Z*R\)3R_VA:W]WI6JZM#<RIJ_@G38'MO)TFXAD,=SYB226[+"
MZ>8RQ?L3VO\`P5C_`&X_AKXA^*'P_P#VX7\):)X=\:WG@:>S\732?;[C4[#1
M=!UV>ZB71_!>HPBR-KK]I#&SW"3">.<F)H]E?=7_``<&@?\`#(7P\]_CKH)_
M\L[QI4'_``;UC_C#_P")H]?VB?$V?_#=?#$?EZU^5K+'_KY'(5F><K+GEDJ_
ML_[5QKGSQITFI>T]JYIMWOKW=TW<]+VJ^IJK[*@ZOM++]S!+D3BM;+WI7OOT
M+/A']BW_`(*]6GBGPU=>*_\`@H+H%UX8MM?TBY\1VVG#5+O4+G08+^WDU>UL
M;:[\"6-M<7=Q8+/';1W-W:P-,RK-/'&6<?NU$KI'ANH7D_+\S8Y;Y>!D\XQC
MFI=J^GZG_&E/0_0_RK]3RS)\/E2JJAB,?657EYEC,;B,7RN*M>FZ\YN%^JC9
M,\Z=251IN,%;I&$8KYJ*5S\T?^"MGQ<^)'P1_8G\=?$#X4^+M5\#^,['Q-X!
ML+/Q'HK0)J-I::IXHT^TU"*W>X@N$B-U:N]O)(D8E\F22-759'#?$_\`P0R_
M:>^/?[1%O^T7%\;/BCXE^)"^%;GX:GP\?$<EI/)I(UB+Q@NIK:S0VEO*$NQI
MUD98W=T#0*Z*K,[-])?\%P/^4>WQ$_[''X9?^IAIU?GC_P`&Y7^J_:L_Z[_"
M/_T#Q[7PF8XO%Q\3<HPD<3B%A998YRPRK5%AW-K$7DZ*ER.3Y8W;C=\L>R.R
MG"#P%:;BG-5$E*VJ5X]3^H.OE[]JS]K?X/\`['GPUN?B3\7==DL[5I7L?#OA
MS3(HKOQ1XQUD0FX31_#NFRRP)/,(U\R\O;F>UTO3+;=/J-]:*T3-]0U_$U_P
M72^)OBOQ?^V[JO@;5;NZ'AGX5>#O"FD>%--+E;.)O$>D6?BG6M6CB4*IO=1O
M-1@LKFXY<PZ+81$XMX@OT?&O$4^&LEGCJ,/:8BK6AA<.FKQC5JJ3522V:@H-
M\KTDVEL882@L165.3:C9RE;>RM>WWGVOX>_X*%_\%.?^"AGC#6O#7[%W@'PU
M\&_`.CW2P:IXTOH=-U5M"@NE+VR>)O'/BK3K[25U.>WV2KI/A3PE+K4*NTL,
M=S`@N1]'67_!-K_@IOXD@_M;QK_P4W\4Z'KTT:S2:=X33QKJ.C+<;=S1)<KX
MA\&1)%O/RR0^'XOW?'D+@+7WW_P2^^&_A/X<_L+_`+.]IX7L8+4^*/AYHOCO
MQ!<PH%DU/Q)XRMXM9U:\N)5.;AU>XCLK=W)V65I:QHJ1JJU^@B\*H'0`#]*X
M,KX:J9C@,+C,]S;-<=B\51I8J<:6.K8/#476BIQC0H865.$;0=I/J_/4JI7]
MG4E"E"G&"NDI4X3EI:[<VKZ_D?S]>'?V2?\`@M/\+O&>@0^$_P!M3P-X^\'S
M:I;P:MJ/CF2ZUYM-TKSE>\NKWP_XI\&:I>W3>09!#;:-XD%W<3A;=KVQAD:]
MB_>[P];ZU::%I%KXCU.TUK7[?3K2'6=7L-,;1K+4]3CA1;V_M-):]U)M-M[J
M</-#8G4+TVJ.L/VJ?9YC;%%?395DV'RCVZPV(QU6G6E&2IXO&5\7"E9)?NO;
M3GR)VUM8QJ5742O&G&SO>$%%MVMJTM3X]_;>_:\\+_L5_`S6OC%XETFX\1WA
MU*R\,>#?"UK<QV4GB3Q=JMO=7.GZ?/?R13_V=I\-M8WVH:I?+;7<EO8V4OD6
MT]S)#!)_/1\$/VA/^"J/_!4SQQXTLOA5\9-`^!7PY\'OITGB.Y\,Q+X7TCPX
MFN/J+:-IMM?65CKGC[Q!J]S:Z9?2^6^K16'F6DL\MSI"-;1W']*/[3_[,?PL
M_:S^%&L?"7XLZ5=:AH.H3P:EIU]IUR+36?#NOV4<\6GZ]H=T\<T5OJ-I'<W$
M6)X)[6YMYY[6[@F@F9*_G%U/_@F-_P`%'/V$/&FL>/?V(?B2WC[0=29(KW3]
M%NM)T;Q%?Z9;RM+8VGBSP-XKEE\,^(3:EF2";3;N_GB-Q=3P6NFF>3;\1QC2
MXA_M3"5XK,<1PU22EB\+DM6=+,)RBK5?:J')*=)-^["-6+DM>:+C9]&&]ER2
MC=1K-W4JD8R@EIHN:[O?LN_H?7Y_X).?MS20MJ`_X*H_%YM:*;S;M8?$(V/V
MH`?)]N'QC#M%D!?-_LA&13GR'(VGAYOV7_\`@N5\#M0MY_AI^U#X9^->DK=1
M#[!X@\16&I7,L+2JK-J-A\4?#+"WMR-TLXTCQ1+>I$H$$LDO[NO)U_X*@?\`
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M?IL4Z6%MZ/7G7PK^*WP^^-7@;0_B3\,/%6F>,O!7B6`W.CZ[I,ADMYU1_)GM
MYHV"3V=]9W"O:WUA>0P7EE<QR6]S!'+&RCT6OUW#N#H473J^WA[.')6<E4=2
M*BDIN:LI.6[EU=V]3S0HHHK8`JK=6R7,,D$B"2&:-XIHV&0\;+M9._WE)!^5
ML_SM44FDU9JZ::=^S5FOFM&'Z._S6Q_!_P#LS:BW[('_``53\+:7KK'3+#P5
M^T/XG^&.K2S9ABMM`\4:CJW@-;^3>%/V9+#7[?4@9`J_9XEDW`$-7]WR_=7'
M3:,<8[>@`Q],#'I7\;'_``7<_9[U#X7?M1Z)\>M"M)K/PS\;=&MKJYU"V5H8
M[#XB^"H;/3-40RH1Y=S?Z1%H&KQ$GS)Y$U&2,MY+8_I(_P"">?[4EA^UI^RS
M\-OB4U];S^,+#2;?P=\3+1&!GL?'_ANV@LM8EGBW9ACUV(6OB>Q4@_\`$NUJ
MU4L)$D1/RO@.:R;..(N%Z[Y:E/'5,=@5+W76PU;WYNG%](W4I6N=^+3JTZ&(
M6MX^SG9?:BD[OY=6S[AHI`<@$=Z6OU1--)K5-7375/9G`%%%%,`HHHH`****
M`$(R0?0__KK^*/\`X+H_$Z/XB_MOMX*TN;[=!\*/`7A;P4T5L3.QU[6);OQ9
MJ-NL:`GSXX_$6G6[Q!@XF@8'`;:G]@7QU^,'A3X"?"3Q]\7_`!K>PV7ASP#X
M8U3Q!>[W"RWTUI#_`,2_2;,$CS+_`%G47M=+T^(<RWMY;Q#[^1_%-^PE\.O%
MG[>G_!132/&?C*V;5-/E\?:K\?/BE/(KRV=MI&C:R-=M](E,BR?Z%J6NRZ'X
M7M8C]VSN3A1'#&B?EOB3B)8N&5<-X:\L5FN.HN<8W;C1C)4[R2O:+YYRE=:1
MII]COP$5%U*\K1C!<J;_`)WRM6ZO32_G8_M"_9G^',OPC_9]^"7PRGC$5UX#
M^%'@+PKJ"*,+_:FC>&M-LM3;:22I?4(;F0@$C,G7(KW!NG]/7_\`5U_#%,C_
M`*=>_.#S_AV.:D(S^'/Z$?UK]+H48X?#T,/32<*%*C1A=O6-*,87;[VC?U.&
M3YI2EO>3;T:NV]?^'/X-?^"OKA?^"B_Q];.2M_X'/RD;MW_"!>%7``!^]@;L
M8SM['BO[F_`DBWW@/P;,Q++<^%/#TV<Y)\S2;.0'(X/7GJK?2OFWXH?L!_L>
M_&CQOJOQ(^*'P(\'^,/&^N?9/[7\0:D=6CN]0-C:0V%HUU'9:E:VTKP6=O#;
MK(T!=HXT\QG9%(^M]/L+/2K"RTO3K:*ST_3K2WL+&T@79!:V=I"EO;6\*#A(
MH(8TCC4<*B@#I7R/#'#.*R3,^(,=7KT:E/-\8L12IT^=NFE.<ES.?5J5FMNQ
MU5Z\:E.A"/,O91LT[))VCMOU3[6/YO\`_@J__P`$F$\5+XB_:?\`V6/#GV/Q
MC:"XUOXG?##P_;B$>*!&WVF^\7^";"W")#XH0^;=:WHEM&$\1X.H60CUJ&6#
M6OYR_CS^T-\1_P!H.3X;77Q5N'UCQA\-?`MK\,W\57S3'7O$>BZ/K.JWVB2^
M(S/A[G6=-AU*32I]3ES>:E#;PW.I[M1:>XO?]'Y@&!4]#7Q/XT_X)Q_L0_$/
MQ1K7C3QC^SE\/]9\3^(KZ74M;U4VVHZ?)J5_<-ON+NYM=*U"QL6N+ER9+J5;
M57N9GDGN#)/+)(_SW$_AU/,L16Q.2XNG@(8Z4)YE@*L/]EQ%2DW*E6I.FE*G
M64I-2YOW<DE=;WO#XM4TE54YV=X-3?N725K/IIY?Y>W_`+.+Y_9[^!`'/_%F
M_AB#QW_X0O0P?RY'UKV>7/ER;<YV-C`R<[3C`/!.>W?I6;HNB:7X=TC2M!T2
MSBT[1]#TZQTG2=/MQMM[#3=,M8K*PLK=#G;!:VL$4$2Y)"1KDDY)U:_4,/"=
M*A2IR<7*G3IPNE[K<(1CL^C:O;8XF[MOSN?QO_\`!2+_`()J?&?]FGXT:O\`
MM+_LZ:#K6O?"V[\7)\1K-_"MI+J'B'X0^)SJG]O20W6E6L4MU)X:LM9S>:)J
M=K;W<5E;"/3=5$/DQW5W^H?[)/\`P7)_9\^)'AG2?#_[1MT_P6^)UG!'9ZQJ
MMQIVHW_@#Q#>PJD4NHZ=J&GPW][X?>Z=7ENM,UNV2WT^1BD>KW<>UA^[$D*2
MY#\J5*E3C:01@Y!!SQU&<'N#@8^3?BC^P=^QY\9[VXU3XC_L]?#;7M7NVWW.
MM6^B+X?UNYD^;][<:QX:DT?4KB4[SNDGNI&?"[RVT8^$APEF639AB<=PMF&&
MPE'&U%5QN59A3JU,'5FERN5&>'<:F'DEI3<%:$?=UT.KZQ&I"$,1&4N1*,:D
M7[Z6FCOO:W?_`(-?_AOS]BO^SAJI_:D^!XLC$)?,/Q#\.K($/4_9C=FZ!!XV
M&`L#D$`C!\N\*_\`!4[]B'QQ\5M!^#WA3XW:3K'B?Q-/]@T?4H]'URU\)7.L
M-*L-MH@\3ZA866F'4=0D;RM-"R&TNK@?9TO#/+!%)S]C_P`$??\`@G?8WS7R
M_L]Z?<LS!A;7WC/X@WEBN.<+:S>*FC(R,X;=S7U3\-OV2_V9_@])#/\`#'X&
M?##P7>6^PQ:GHW@[1(]94IC8W]MSV<^L;EV@[_MVXM\Y)?YJ]NE_KA.M2]LN
M'<-0C-.LJ53,L74JT].:$.>EAE1EI[L_WF[T5KRS?U?_`*>-_<EMYN_5_+S/
MH8'(!]0.G3IVZ_S-?B]_P5[_`.">?B+]K_P)X<^(_P`*((KGXS?"NUU*UL]`
MFEALQXY\'WTXO[SP]:WD[+;PZ[IMTLEYX=-W)%:3SW5]9SL@N8G7]H0,``=`
M,?E2,@?&<\'/!QGV/L:]/-\JPN=Y=7RW&1;HXB*3<=)PG%IPJ4Y--QE%JZEN
M11JRHU(U(?%%_>NJ^9_))_P2O_X*,Z-^Q;:>*/V3_P!K/2_$WP]T+3_$^H:K
MX9UW5]`U;[7X&U?5)$37O#?BC0DMCK%KI%U?PG5;&^L["[-M?W6I-=`VMY!)
M9_T4Z#^W9^QMXBTZ'4M*_:@^"$EK+&K@W7Q#\.:9.NY0Q$MEJ=]:WENXS\T4
M\*2Q'Y)55P5'??%O]F+]GWX\P)!\8?A#X#^(1BC:&"\\0^'K"XU6VC8$%+36
MHHH=8LUP>%M;Z$*0&4!@"/CZ_P#^".W_``3OO[A[AO@!#:[^MO8^//B/;6HR
M<_+`OBPHOU&.@%?,9;E7%F18>&78/%95FF!H)0PD\=/%87%T:2=U2JRHT<13
MK<NRGR0E;=O9[3J4*K<Y1G3FW>2C:<7HKNSM9W73=:/N<S^TS_P5^_9`^!WA
M'79O!OQ*T#XS?$-;*X3PYX/^'ERWB"SNM6>-H[,:UXELP=!TG3TNO+:_;^T+
MC48[=9#;Z=.Y7'\ZG[!W["_QN_;N_:%3XY?$#0M1TCX177Q$O/B1\1O'6IV,
MNGV'C'5+O7Y?$NH^&_!\=VGF:K/K5_.UM>W=NMQ9:-8R3RW%R]Z(+2;^IGP%
M_P`$R/V$/AO?6VI^'/V;/`%QJ-HT;P7GBF'4_&[QR1,'CD6#QAJ.N6:R*P!#
MK;*V1R37W'9:?9:;:6UAIUI;6-C9Q)!:V5I!%;6MM!&-L<,%O"B1111KQ'&B
MJB#A0!6.+X4S+B''8/%<38O"/!8"?M:&59;&M[*51Q2<L1B:ZC.K)M*]H0CR
MKEY5?2J>)C0A.-",N:>DJDGK;M%+;K;U?<EMT\J&.,*$"*J*@&`JHH55&..`
M`..!T'`S7YW_`/!65@/^"?'[2H[_`/"(Z+^7_"9^&^WMU)[#D\5^B]</\1?A
MMX&^+?@[7OA_\1_#EAXN\%^)[-;#7O#NJ+(VGZE:I/%=)'.(9(9U,=S!!/%)
M%-')%-#')&R.NZOL<QPD\7EN+P5.4(SKX2KAX2FI*"<Z3IQNH:I*ZVZ+Y'+"
M3A.,M^62;OUM]VOW'\=?_!$C]I?X'?LV?%KXT:Q\;_B'HWP\TOQ/\/\`0M,T
M/4-:BU*2VOK^R\1_:;FS1M.L;XK,EO*LZB1(]R1OL+X8+_2./^"J/_!/SD_\
M-0?#XD]S%XF';T_X1[]:D_X=7_\`!/O_`*-?\`?]_P#Q+_\`+ZC_`(=7_P#!
M/O\`Z-?\`?\`?_Q+_P#+ZOAN'\CXPX=RNAE>%J\/UJ=&56?M*T<>IWJ3@[/E
ME9V2DM%;1=6==6KAZU3VDE65TE))KI;:]]K?G;H=]\+OV^OV0?C9XWTGX<_"
MKX[^#O&?C76X[Z32O#NE1ZV+Z^73;.74+UH3>Z1:0?Z-8V]Q<NIF5BD3E0^T
MK7V$"<GC'`_7-?)GPD_84_9)^!'C&#X@_"'X'^$/`WC.UL;[3+;Q#I0U.?4+
M>QU*(0W\%NVIZA?QV_VJ$>3-+!'',T)>$R>3++&_UF!CG)/0<^W^/>OM\M_M
M3V#_`+6^I?67-_[@\1['DLK<RQ#<E*]](:=;;G+/DO\`NU*W][?9;VTWN(PS
MCTS@CU[_`-.*_E._X.+T0>._V8G55W'PG\1E9@!NVKJ_ADHA(_A5FD*CU9_3
M`_JR(SZ]<\5\[?'#]DO]G3]I*X\/W?QS^%7ASXCW/A6&_@\/3ZZ=0672H=4>
MUDU"*VET^]LI#'=265J\D<S2QAX0Z*C-(7\SBO):V?Y)B\LP]6&'K5W1E"K4
MYG!.$TY)\OO1]U*SC9W_`!UPM;V%>-5WM%WLNJM:UGH^N_0^&/\`@B(D8_X)
M]_#-U50[>*?B67Q@%F/C/45+-W9@L:+N).U`J#"A17ZXUYM\*/A!\-_@=X,T
MSX>?"?PGIO@CP3HTE_+IOAW2!,+&UFU.\DU"^F4W,MQ<O+<W<TLTCRSR,2Y`
M(4*%])KT,DP$LKRG+LNG*,YX+"TL/*4.9PDX*S<>?WK-ZZ];]#.K/VE6I-*R
ME-M+R>VVWH%-;ISTX_F*=2$9&*]1?U8S7]6/P<_X.#F`_9"^'N6Z?'70.!CC
M/@[QIP><Y/TZ<BH/^#>M@/V0/B9GC/[1/B;;VSGX=_#$<?WN2!D<9.,YXK]B
MOC1\`/@]^T1X:M?!WQJ\":/\0O#%EJMOKEIHVMF[%K;:O:6]U:V]_"UC<VEP
MD\=O>W<((FVLD[JZL-NUOP7_`&?O@Y^SOX9N_!OP4\!:-\//"]_K=SXDO=&T
M/[6;:ZUR[L[#3[C4IGOKF\N7N);+3+"V.9_+$5K$JHN"3\7_`*M8O_73_658
MB@\+_9[PBH-5%5C4Y:<;IQM!I\LM97_&QU.NOJJHI>]S-MV5K-I^M].V_GJ>
MQTAZ'Z'^5+0>>/6OM#E/R)_X+@LH_P""?'Q%!(_Y''X98&0.?^$QT[ID\\?7
M'7WK\\_^#<L8C_:L#'&9OA(0",'B+Q\<\\XQ@YZ5_1O\6?@]\-?CIX*U#X=?
M%GPEIOC;P5JMQI]U?^']6^T"SN+G2KR._P!.G9K6:WN%EM+R*.XA:.9=KH.H
MR#Q?P0_99_9__9NA\0P?`[X8^'_AQ'XKETV;Q'_87VYGU=](6Y33?M4NH7E[
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ML?M=^$/&'AS1?`D]QI7A;Q>NA7_]O^$;*>[:Y/AOQGX6N8H=7ET_3)Y9QI>I
MZ;%=7MI9&/3)=*N(H(;MOWR\+?\`!1']B/Q;IT>IZ3^U#\'DMY$601:QXML/
M#>H1JW19],\1-I>I0N""I$UG&6(RH(KVCXI_LW_`7XWVXM_BY\(OA_\`$+9&
M88;KQ/X8TK4-3MHSC*V>KO;+JED.`?\`1+R#Y@&'*J1\<W__``1[_P""=U_=
MB[/[/5A9D/YAMM/\:?$*SLV;WMHO%0C49).(PF,G&!Q7S>797QADF'A@<)CL
MES;!T(QIX6IF2QN%Q=.E&UH59X>GB*=9Q7NQERP:CIKHC64\-4?/*-6G)[^S
MY)K6U_CV^7_#Z7Q$_P""LW[!?PWDAM[WX_\`AWQ3=S75O;_9/A_8:QXW,*S3
M)#)<SWNA6-QI<4-L',]P/M[7`BCE6&VGG,4$GWUX-\8>&?B!X5T#QMX,UW3O
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M;^4=3U=+"YO]-MX=(TI9HOME[<WD0:6:*VMDGN&\NO%/`'_!7G]@'X@QPM'\
M>=+\(74PC_T'Q]H7B'PE-$TBJ0LM_?Z8=%!1LJ[)JKQ$_P"KD<#-???CCX9_
M#SXF:<^C_$3P1X4\<Z3(K(VF>+?#VD^(;#:X4-MMM6L[N*-CM!WHJN",A@0#
M7Q-XK_X)0?\`!/OQA-+<:A^S;X1TV>9R[OX7U+Q/X3C!.#B.T\.ZYIME"N1D
M+%;(`2>.:X<?2XJ6,G5RVOD\L"XKDPV,I8J-:,].:4J]*?O<VO*K)06FN@Z;
MH6M4C4O?XHR7=;)I]W_21Z9>_M[_`+$UC82:G<_M0?`_[,83+OB^(7A^[F=%
M#,`EG:WL]W*S8.V.*`O(<*%8D*?Y9_\`@KI^TA^RO^U1\3_A[:_LL^"T\0>.
M-,DUJS\:?$SPWX4GT*7X@2ZBUC%H.AV>G1V5KK/BF[TZ2&]FBUO4].%P%O9+
M#36N;0SF/^A6S_X(S?\`!.^SN5N3\#KB[V-N$%[\0?B%/;$Y!PT7_"3)O'8A
MB01D'-?6OPA_8\_9?^`LBW/PB^!_P]\%:DJ>6-<L-"M[OQ'LR25/B75?M^OE
M3GY@=2(8!=P.U<>%F^2<4<282679@\BR_"55&->KAH8C%8JR:;="5:T:3=K)
MZRCT;T.BC7P]"?M(1J2DE)).5HJZ2N[;^FVQ\,_\$8OV;_BU^SI^RK>6?Q<M
M;_P_K'Q"\;WGCO2?!&I-+]N\+:+=Z3I6G6PU*U<XT[5=6^PF_NM.*)<6<3VD
M-ZD5W'+;P?KS3(XQ&-H)([9QQ@8P,`<<?TZ8%/K[+*LNHY1EV$RW#RG.C@Z,
M:,)U'S3E9N3E)ZW;E)O?38Y*E256<JDK<TG=V5ELEHEMH@HHHKT"`HHHH`^+
M?V]?V3=$_;%_9R\7_":Y^S6GBO`\1_#G7+E#LT3QUH\%S+I$T\RJ[P:=J227
M&B:PR*S-INHW#(DDRQ(W\FG_``3N_:_\9?\`!.K]I?Q-X!^+FGZKHW@'7M<'
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M7PW9:E);/)IR7`FEU;P;?/;)]HWWFFW.FWOV^+5/[!_@K\=_A-^T)X*T_P`?
M_![QOH7CCPO?QJ?MFD78:XL+EE#/IVL:;,L6HZ-J=OG9<Z?J5M;7<+@AX0.:
M]SAGBW+^(L.^64<+F%!*.,R^J^2M1J*RERPE9RBY/11NXWY7J95\+4P\K<LG
M#3EG;1W2LO7]%<]?HIH8'Z]QUIU?5)WVO\TU^9S!1132V#@^G6ANV_>VS?Y`
M.J*69(5+R21QJJL[-(P1551N9F9B`%502Q)P`/K7+^-O'?@[X;^&]4\8^//$
M^A>$/"NBV[76J^(/$6IVFDZ58P("S//>7DL42L0,1QAC)*Y5(E=SMK^4?_@I
M3_P67O?C-I^M_`G]E.YU30?AUJ*SZ3XN^*I%QIGB7QQ93!X9M'\(V3>3>>'_
M``U?(R_:=4O%AUS6+61K,6FCV_VJ&_\`G>(N)\LX<PDZ^+K1EB'%K#82#YJ^
M(JMI0A&$;R2<FKMK:YO0P]2O-1A%OJWT26K?3H<?_P`%G/\`@H5;?M!^,[?]
MF3X-ZN-2^%7P_P!?$WC'7-(G%Q;?$/XA6DK6]O86$EN"U[H'A*X:2WM61VCU
M;Q$UQ>P12VVF:)J%S^S_`/P2!_8BG_90^`+^*?'.F-8_&3XRQZ7XC\6V]Q%M
MN_#'AZ&*9_"_@UBRCRKBSM[F?4];A4+LU?49+64.-/@>OSJ_X)&_\$IM4M]2
M\-_M5?M,^')+$6/V76O@_P#"[6;1X;LW05+K3_'_`(PTZY4?85@&+GPMH-Q"
MLJW31ZWJ"0O;V4%S_44HVC%?*\'Y-F..S/$<8Y_2=+'8RG&GE^#DK+"8:T4J
MG(W>$Y1C:S2;3<[6DF;8J<(TXX6G:48M3G).Z<[?#?K;1NVE]-Q%4(,#I@`>
MP'2E)(''7M_G_/K2TUAG&>,'.??!']:_2[6CRQ5MENU9-ZN^KNE=]=3B.*U3
MXE?#S1+Z?2]9\?>"M(U2U9$NM.U3Q1H>GWUN\JAXEGM+N_BGA:1&#(LB*SJ0
M5!S6KI/BWPOKSM'HGB;P]K+J"632=8T_4'4#&2RVEQ*0!D9)'&1ZU_,3X8\%
MW'C?_@KC^W!9P_#G]F?XEFSTM;F32_VGH_/\,Z?^\\"11WWAJW7P]XF7^W<.
M+>9YK*-_[.DE\N>-6V'A/VP?"5O^SO\`'+X"_&WXI>&?V:/A=X+T+QK$EOX:
M_P""?&O7G@WXP^)VMC8ZGN\1V>JKH5K?Z%:26C64EQH>F6=VT>J'37NHGUJ)
M[;\_?&=>-"OBYX.G&AALQJX*K>K*"C3HUW2G7E4G34?X=JG*GI>VK.R6%22Y
M:BDW!2W2U:O;^O1OJ?UI9Z<]>GOQVI:Y_P`*:Y;>)_#7A_Q)8Q7T-CX@T;3=
M;LH=4M)[#4X;35;*&_MHM0L;D"YL[Z.&X2.ZM;@+-;S+)#(H=6`Z"OOJ=15*
M:J1:<91C.+6J<90C)6ELT[Z-'(]'8S]4U;2]$L+G5-9U*PTC3+-!)=ZCJ=W;
MV-C:QEUC#W%W=20P0*TCH@:615+LJYR0*FLKZSU&TM[_`$^[M;ZRNXHY[6\L
MYXKJUN8)5#1307$+O%-%(I#1R1NR.I!4L""?S;_X*]`_\.\_VB^2,:3X0X&>
MC?$7PB#G!Z$#;T!*LPSAB#[-_P`$^N?V)/V62#P?@EX`/KG_`(D=HN21@$]R
M>_7G.:\I9G.6>5LH]E:-++J6.C6;_B.==TG32_NI7[FG(O8NIS>\JG)R]URI
MW_/[C[(HHI&SM;'!P>?P]P1^8(]C7LOTOZ&1BZWXD\/^&[4WWB'7-'T&Q!P;
MW6M3LM+M0?0SWT]O%GV+@]3V-<YH?Q5^&'B>Z^P^'/B+X&U^]."+/1?%N@:I
M=$'IBWL=0GE/'/W.A![U_.Y^RK9>'OC!_P`%!OVJ-!_X*#V^G:]\3?#>K&/X
M$?#_`.,12Y\!6/A&/Q)K8ED^'_A7Q&6\*:LJ:'%X9GTZ6WLKN:\M+B^U.+S[
MB:]NX?T2_;N^`'[$.A?LT_%+Q1XO^'OP?^'U_P"'?`WB+5O!WB[PEH/A/P3X
MVT[Q39:7<W/AD>$]7T"/1=6N-2N-9CM(K72H+B:UU%G-O/:S(^%^3P_$&)Q6
M!QF8PHX/#TL-/%1C0Q6(JPQ+6&JRI)UXJGR4/:2A-T]9^TC:2?+:^[I)24>9
MM_W4VM;;-:/KL?J:KHWW65O]T@_RIU?E#_P1J\;?'/QY^QAH>M?'2Y\1:IJ-
MOXS\1Z1X`UWQ6MVVNZ_\-+&RT231-1O+Z_9[[54AUBX\0Z3I^HW32O+INF6B
M1W-Q"D<K?J\*]W+,=',L#A<=&G.BL51C65*I\<.;2SVV:>Z3ZV1G.#A)Q=FU
M;9WW5^ES/U/5M,T6QN=3UC4++2=-LU\R[U'4[NWL+"V0L$#W%W=2100H794#
M2.H+,%&20*X@?&#X3GD?%#X=8)P#_P`)KX;YX+=1J?HK'MPK''!QT?BOPAX7
M\=Z#J'A7QKX<T#Q=X8U:-(=5\.^)]&T_7M"U.&*:.XCAU#2=4@N;"]BCGBBG
M1+FWE5)HHY5`D16'\Z?_``5&_9[^`_@C]JS_`()F^'_!GP7^%?A+0?'OQQOM
M&\;Z+X5\`^%O#>E^+=)3Q[\$[==.\26&B:78VFM6GDZKJ,`@U&&XC,-_<PLK
M1SR(WG9_F>,RC"/&TJ-"M1A5P])QG5G"HWB:U.A%W]E.*495%)ZW:5DT[%4J
M?M9\E[-IM-Z+35ZO2]MEUV5W8_HBT/Q_X%\37;:?X=\:>$_$&HI%).]AHGB+
M1]5O$@B9$DF:VL;R>811M)&KR%-JM(@8@NH/6@Y'_P!;%>-^`OV>/@-\+=8D
M\1?#/X+_``G^'FO364NESZUX&^'/@_PEJL^G22+)+8S:AX?T?3[J2TEFBAED
MMFE,#O!"6C)C4CV49[\^]>QA_K/(OK2I*HM/W,IN#7\UIQBTWO:VE[&;MTO;
MS_K]-!"3S[?X9_G7)ZAX]\$:1>2Z=JOC'PKIE_;[!<66H>(=)L[R!I$61!+;
M7%Y'-'OC='0.B[D=77*L">I<G#`=2,@^_`'''\Z_E8@\'7_C3_@L1^V%I=EX
M#_9J^(LEOH$=U_9?[3]O+>>$+98M)^'D/VW1((]&UX2^((A<BW4O9*D&FS7.
MV12Q+>-GV<U,G_L[V=&-9X_'K!OGDXQIITN?GNM6[JRCN[LTI4_:N2O;EBY?
M=TU/Z?\`3?'?@K6;R+3M(\8>%M3U"<OY%CI^OZ5>W<_EHTK^3;VUY+-(4B1Y
M'"(VU$9V(4''65^>O[,WP>\/>$_&5QK_`(O^"?[!_@/Q/9Q0Q^!M<_9NT#3;
M?QA'<727MOKD5S>7_A'0;^U@FL7A@C.D7,DEQ%+>17<8A"9_0H9[UZF`Q%7$
MT74JJ"E[244H*27*K6;4_>3=]F9M6=NW7OYZ!36;;C)`'?/'`Y//3@>M.K\-
M_P#@MQX_^/\`X/\`AO\`!:P^'>M^+_!/P1\4>,]1TG]H/Q[X$6_37M!T6:3P
MY!HEK>ZCI96_TW0;NRO?$UU<_9G2'5M2T[3=)N[F.&4VFHXYQF<<HRW$YC.C
M4KQPZIMTZ2]Y^TJPI*3>O+"#J<]25GRTXRE9VL53@ZDU!-1O?66VB;^]VLO-
MH_8/6/BY\+?#UZVG:]\2O`&BWZL$-CJWB_P_IUZKD@;6MKO4HI@V2!@H#R/6
MNRTG6M(UVTCO]$U33M8L)1F*^TJ]MM0LY>F?+N;22:%^O\+FOAOX'?L\?\$_
M;CX<Z+-\*_AS^SKXV\)7VE6[_P#"2S:/X)\?:CKD;VZ[KKQ#XEUZ#6-<U&_D
M!:2\&KW\MS%-),DT:,-@^GOA#X,^#G@30;W0/@EX=^'?ACPO!JUX][I7PUT[
MP]IFC1:VX@^W&[MO#D<5HNIE%MQ<><JW(01(Z)"D").!Q.,K^RE7>`Y:E)5.
M7"UZM:4.:SC>4X14M&M59;V;ZN48V?+S.W5K3HGY;WL>LT$X!/I11G'YXKU'
M>SMV,S%U;Q%H.@FT&N:WI&C?VA=Q6.G_`-JZC9Z?]NO9?]79VGVN:'[3=2'B
M.WAWRN>%0UL;@0"&&#CGJ#GI@YQSV/-?S[?\%YFU)=&_8U_L?[&=7/QXNVTL
M:AYJV7]I+::)]@%Z\"O.EK]K:$3R6T9N1&"(2'R3^F"W?_!0%K4*-%_9!)V`
MLW]N_&,)N&&<[3H)^4D$D;]W^T3U^<CG[>:9ME[P>)G'+EA'"M0H5:ZJ/$4?
M:24_9Q:IM<KM>W-LM39TK4HU$U>3:Y6TM/=M*[\V^;M;Y'V%I'B+0-?^V?V'
MKFCZU_9]T]E?_P!DZE9ZC]AO8N)+.\^R33?9KJ,G$D$WERID;D%;-?S^_P#!
M!HZHWAW]L5M:^QKK3?M`(VL?8#.]E_:C66J?VA]BDN?](DLVNQ,UL]P/M)A=
M?/8N?E_H"KNR/,WF^68;,'2]BZ_M;TM?=]G5G3MKK=\EVNC=N@JT%3J.$9<Z
M2C:7>\4W]S;7R"BBBO6,@HHHH`IWE]:Z?:SWU]<V]E96L4EQ=7=W-';VUM;P
MIYDL\]Q,R10Q1H&>221E1%!9B`":KZ5K.EZ[80:KHFIZ=K&F709K74=*O+?4
M+"Y6.1X93!=VLLUO,(YHWA<QR,$E1T;#*0/E[]N[:?V,OVGR<Y'P-^))`R>W
MA74@#D>FWKU!YSBOF?\`X(R#_C77\##R`+GXEC!QD;?BAXOP.@X5<*``.%'3
MI7C3S.2SREDZA=5,MJX]U;JZE2Q-.DJ=MM8R;V-%!^R<WTGR/UM?^M#]30<@
M'UHI!T'T%+7LF:OU.>E\6^%X=;3PS-XET"'Q)(@EC\/R:QIRZW)$R&1)4TIK
ME;YD:-6=6$!4H"P.T9K2O]4T_2K&YU/5+^QTS3K.)I[N_P!0NH;.RM8$^_-<
MW5Q)'!!$HY:22144=6K^8;XT_LZ:-^T__P`%E?C]\-K[Q3XA\">(+3X':#XQ
M^'?C_P`*WMU9Z]X'^(7ASP[\-Y]`\161M[JU%U';I<7UK>V+2PM<6-U/]GN;
M*_CL-1L>A_:G_:G^.WPX_9<^/O[&?[=/A\VGQ,UGX>:A#\'/C_H-F\GP^^.5
MOH>H:?J$-C=R0V\5II'C.:VLQ]HA:*PANY=XO['2IVM9=4^%EQDZ$,XKXO!*
MCALOQ&-PF&Q,:LJM*OB\%"$WA\0E#_975YX^SJ5.6G.[46VG;J^KQ?LU&I=R
M4925K<L9)7:N[2MS)-7N?TNV-_9:G9VVHZ;>6NH:?>PQW-G?6-Q%=6=W;RJ'
MBN+:Y@>2&>&5"&CEB=HW4AE8@@U:KX6_X)F'/[`_[+!R2#\*='(.2<@W-Z01
ME5PN/NKL0*N`$0`*/NFOK\!B?KF!P>+Y>3ZUA</B.77W?;4H5.7773FMKJ<\
MTHSE%.ZC*23[I-I/YK487P>V!C/KS^GO^E<3XA^)GP\\)3K:^*/'G@SPW<N,
MI;:_XGT72+A^_P`L-]?02D8P<A.ASTK\\/\`@KMXZ_:)^'_[(OB#7/V<F\06
MFN/XAT:Q\<:YX2AN)?%'AWX>W-OJ1UK5=(EM$DN].!O8]+L]1UFR07>D:7=7
ME]'/:B-KJ#`_8.^"7[!7B7]G[X>^(_".A?!GXR^+=9\(^'[[XD>//'.G^'/'
M7Q#U;QO=Z7:77BAO%<WC#^V?$&C7RZW+?#^Q9Y;:WL8\1V\4D06:7R:^;UUF
M]3**%&$)TL-3Q4L5BYRI4:JJO2CAHPIU76G32O6=ER)K17-53C[.-5MN+ER<
ML?BNDKZ=-;V?7H?J1H'BGPWXJM6O?#7B'0_$-FNW-WH6JV&K6P##*YGL+BXC
M!/.,L,CM6_7AWPI^&W[/_P`/+[Q/:_!3P9\*/!=_J%Q9W'B^T^&VB>%=%N9[
MAA+]A?7+?P[;6TB\><;5+M5"J\Y@`+LP]QKVZ$IRI0=1P=1KWW3;E"]_LMQ@
MVK6WBM;F+T>B:\GOL%%%%;""BBB@`IK+N&/?KC\>.>O3Z^E.HHWT`_+;]O#_
M`()8_`_]LRVNO%L&WX9?&V*V*67Q&T'38IH=<\J,);V/CC18GMX]>M%"10Q:
MC&]OK5@BIY-[);1-9R?S`^/_`-F;_@H/_P`$T?&UQXWT-?'/A/2;6=A%\6?A
M;=7VM?#O6;&WE;RU\0F.![.UMI0C2+H_C?1[1Y(OF2UE1=X_O'QGJ,_A5>XM
MH[F&6"9(Y(95*2121K)'(C##)(C@JZ./E=6#*PX(QQ7PF?\``>5YQB/[0PLJ
MF5YK'WUC<)[G/4BDHRJ13LFMW*"C-[MO=]='&5:5HR;J4]N26MO--Z[*V_4_
MD@^!_P#P<'?&KPO#8Z7\=/A+X3^*$$")%+XD\):A+X%\0SJJH#/<V)L]8\.W
M=R_SLRVEOHJ;V4>7#N*K^A7AG_@X*_8]U6VC/B'P)\;_``Q?;09K;_A'O"VL
MVR/M#,L5W8^+DDE53PIDL[>5A@F%>0/NGXO?\$R?V'_C;<76H>,O@!X,LM;O
M':6YU_P1!=_#_5[B=G+FYNY_!UWHT.H73$_O+C4K>\EEPOF,RJ%KXDU__@W\
M_8PU:Y:;2O&/QW\,1%B5M-,\6^%;Z&-2<[$?7?!&J7)`[-).[^KGG/CT\M\3
M,K@J6%S7*\VII\L98Y25;E6BE*I*,7*327,W*3;;;;>IHYX&;;=.I!MW?*]-
M6KI*_K:Z^[0DUG_@X`_8NL+:272_"OQQUZZ5"T=I;^$?#EB9&Z!6GU'QA;QQ
M`G&7;(`.0&P0/AKXS_\`!Q!XPU.&YLO@1\!=(\--)'(EKXD^).O3>(;N+/"S
M?\(YH,&E6$$R#>P6ZUV]A!*!D.XBOM/2_P#@WR_8ZL;A9K[XA_M`:S"&!-K=
M^)_`]M&PQAE:33?A]9S%77@XD!`Z$'FOK?X5?\$D?V"OA-<07^F_`K1?&&JV
M[!UU/XEWVJ>/2TJ@;9FTC7KNX\."5'S(ACT:,1NS-$J$TI8/Q2QS]G6S'*<L
MI2?+4GA5"53D:LY0FJ-6=_*\'VE'<2E@H-24*DVK>[*Z72[T>MM;=-KG\HR0
M_P#!1'_@J)XUB#K\1/BU917[XN)8_P#A%_A%X-=R49Q+Y>E>"=&DAB).&\W6
M;F-'6-+^=<G^A?\`8*_X(N_"W]G.ZTCXE_'*]TSXO?%^P:&]TW3Q9LWP[\$W
MZL)4FTFPOHHKCQ)JUK,B20ZWK=M%#;3(LFGZ1:7$$=U7[9Z-HNE>'M.M-'T/
M3=.T?2-/ACMK#2]*L;?3K"QMXEV1P6EG:)%;6\**,)%#$B*.`*U`,?Y_S^5>
MODO`6!P&(689KBJ^?9DFI0Q..O*%*6FM.C*<XM+9.?,U:ZMHDJV-G47)3BJ,
M.JAHY6MUW6VJ3L^HU$V#`QM&``!C&!CU],```````4^BBOO5IHOU^[T6R6R6
MBLD<04A&012T4`?-7B_]CK]EOQ_XIU?QOXW^`GPJ\4^+M>F6XUGQ%K7@S1[W
M6-3G2..".:]OI;<SW,B0110B29G?RXHTW;4`J;PG^R#^R]X%U>UU_P`'_`#X
M0^'=<LI1/9:QIOP_\-Q:G:3*`$EMKYK![F"2/&8WBD4H<$<C-?1]%<BP&"4G
M)83#\SESMNC!OGNY<^L7:?,[\RM*_71%*4ELW_7_``R_/<CCC\M0H.<9QQCK
M[#C^GH!4E%%==K;+?_*WY)$G(^-_`?@_XD^&=6\&>/?#FC^+?">O110:SX=U
M_3[;5-(U.&">*Z@CO+&\CEMYUANH8;B/>A*311NN&0&M#PQX9T'P;H&D^%O"
M^DZ?H/AS0;"UTK1-$TJTAL=,TK3+&%+>TL+&SMU2&VM;:%$CAAC151%``K>H
MJ/9PYW4Y(^T</9N?*N=PO?DYK<W+=WM>U]0"@T458'DOQ(^!/P=^,4$%M\5?
MAGX%^(4=GN^PMXM\+:1K<U@&!S]AN;^VFN;3+'>QMYH]S!2>@KRS1_V&OV0M
M!U"VU73/V=/A+'J-G,MQ:W5WX-TG4WM9T(9);5=3@O$MG1AF-H%1H\G8RYS7
MU;17+/`X*I4]K4PF&G47VY4*;ETOKR];*_=ZO4:E)*RE))>;_K[RI9V4%A!#
M:VD45O:V\206]O!$L,,,4:JD<<:)A4CC151$4!50*H^[5NBBNF,8Q5HQ45T4
M4DEZ)627DM!!7FGC7X._#'XCZYX/\3>._`OA7Q;X@^'FJ-K?@/6/$&AV&J:A
MX/UEI[*Z.J>'[JZADFTZ]-SING3M-;NC&6PLY.'MT8>ET5-2E3JQY*M.%2%T
M^2I%3C>+3BW&2:;BTFFUHU=68"*-J@=<#KC&??'/7J>:6BBK_KN`UE#9SW4K
M7S=XO_8\_9<^('BC5?&WCCX"?"KQ7XOUR2.76/$FN>"]&O\`6=2DAMXK6)[R
M_GMGN9W2VABA#O(6\N-%)VJ`/I.BLJM"A725:E3K1C)R4:L(SBI-*+:C)-7L
MK;=^[&I-7LVKJSMU1\U>%/V.OV6_`GB/2/%W@SX"?"OPSXGT&[6_T;7=&\&Z
M/9:IIEXL<L(NK&\AMUFMIQ%--$)8V#!)7"D;B:^E<8_$YHHJ:&&P^&BXX:A1
MP\92<Y1HTH4HRD]Y-044WYM""J&HZ98:O:S66I6=K?V5S%+;W5G>VT-W:W-O
M,I26&>WG5X98I%)5TD1E=258$$U?HK648SC*$DI1DG&47LT]&GW36C6S6CT`
M^4M0_89_8_U74)-5O?V;_@\U]-(99YK;P-HE@)Y2VXR3PV-M;P2N3]YGB)/(
MX5B*]R^'_P`,/AY\*M'D\/\`PV\%>%O`NARW+WLVD^$M!TSP_I\U[)'%%)>3
M6NEVUM%+=21PQ1O/*KS,D<:,[!%QW=%84L'A*$N>CAJ%*3^U3I0@]=_A2L/F
ME:UW;MT^[8*0\CT]_2EHKH:NFG>ST=FT_O5FODQ'F?Q"^#GPO^+!\/GXE^`_
M"GCG_A$]8CU_PR/%&AV.LC0]:B$:QZGIHO8I?LMV!''F6'86V)NR5!KT80@)
MY>1LQM(V@`COD#C)[D`>V.TU%9QH4H3E4A3C&I/EYZD5RSJ<D7"'M)JTI\D6
MU'G;Y;MJS=QMMI)MV6RVM]UCS;X??!_X8?"C^WQ\-/`GA7P*GBO69?$/B5/"
M^BV6CKKNM3!A+J>IBSBB^UWKAFS/+N;YG[NQ/I-%%5"$*<5"G"-."NU&$5&*
MN[NT8I)7;;=EJVV]6#;;;>K?7\`HHHJQ!1110!A^(O#>B>+="U;PQXETNPUS
MP_KVGW>DZUHVJVD-]INJZ9?0R6]Y87UI<*\-Q:W,$LD4T,JLCHQ!%8_@+X>^
M#/A=X6TWP1\/?#.A^#?"&C)<)I/AOPWIEMI.CZ<+NZFOKO[+8VBI!$;B\N)[
MF8HBF2::21B6;-=I16?LJ?M%6]G#VJA*"J<JYU"<E.4>:W-RN23:ONBN:7*X
MW]UOF:_O=_4!P`/2BBBM"3S.W^#?PMM?B7>_&2W\`>$H?BGJ.DC0K[X@1:'8
MIXMNM&5+:-=,N-<$7VZ6R6.TM8Q`\I3R[>%,;8P*L?$7X3?#?XNZ"_A;XH^"
M/"WQ`\./<1W9T3Q=H6G:]IJW46[RKF.UU&">.*>,.RI-$$E5&=%<([*?1**Q
M>'P[A5INA2]G6<I5H>SBH592MS2J12M.;LKRDG+3<=W>]];6^6G^2.?\*>%/
M#?@;PYH_A#P?HFF>&_"_AZQBTS0]!T6R@T[2M)TZ#(@LK"RMDC@MK>%3A(XD
M51R<9)KH***U2222222LDE9)+9)+9(1'+&LR/&X#)(I1U90RLC`@JRM\K*02
M"""".""*^9?$?[%O[)_BW5+C6_$7[/7PDU+6;N1Y;S5#X(T2TOKR67)DDN[B
MQM;5[EW9F9FF+LS,S$ECFOIZBL*V$PN):>(PU&NX_#[:E"IR^G.G;SM:XTVM
MFUZ-H\L^'/P1^$?P@COHOA9\-_!'P]35%@75#X1\,Z3H<VIBV,C6PU&XL+:&
M>]$#2R&+[3)+L\R0J0SLU>IT45K3I4Z,%3I4X4Z<?AA"*C"-W=VC%)+771;Z
M@VWJ[M]WJ%%%%6(****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
'"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
